rosuvastatin

venous thromboembolism (deep vein thrombosis or pulmonary embolism)

decreases, hazard ratio 0.53, 95% CI 0.37-0.75, n = 30507

In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).

PMID:33705531 · both readings recorded this

venous thromboembolism (deep vein thrombosis or pulmonary embolism) incidence

decreases, hazard ratio 0.53, 95% CI 0.37-0.75

Not recorded as a finding: this platform holds no node for the endpoint

In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).

PMID:33705531 · one of two readings recorded this

venous thromboembolism (deep vein thrombosis or pulmonary embolism) incidence during follow-up, pooled individual participant data from two RCTs

decreases, hazard ratio 0.53, 95% CI 0.37-0.75, n = 30507

Not recorded as a finding: this platform holds no node for the endpoint

In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).

PMID:33705531 · one of two readings recorded this

venous thromboembolism, subgroup interaction testing

no effect

No significant interactions were observed between treatment with rosuvastatin and the risk of VTE across subpopulations stratified by demographic, CVD risk factors, or a history of cancer (P-values for interactions >0.05 for all subgroups).

PMID:33705531 · one of two readings recorded this

systolic blood pressure (setting unspecified)

MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08, p = 0.08

Not recorded as a finding: The sentence negates only one tail ('not associated with a significant reduction'), and no sentence in the paper states a two-sided absence of difference for SBP, so no direction is recordable per the one-sided-negation rule.

However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

PMID:34818350 · one of two readings recorded this

systolic blood pressure (SBP)

MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08, p = 0.08

However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

PMID:34818350 · one of two readings recorded this

systolic blood pressure (SBP) change from baseline

MD = -2.27 mmHg; 95% CI = -4.79 to 0.25, p = 0.08

However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

PMID:34818350 · one of two readings recorded this

systolic blood pressure (SBP), pooled mean difference across RCTs

MD = −2.27 mmHg; 95% CI = −4.79 to 0.25, p = 0.08

Not recorded as a finding: the sentence states only a one-sided 'not associated with a significant reduction' (ADR rule 1a); no two-sided no-difference statement exists in Results to support no_effect, so direction is not recordable

However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

PMID:34818350 · one of two readings recorded this

composite adverse events

no effect, odds ratio 0.50; 95% CI 0.15 to 1.72, p = 0.27

Based on three studies (I2=0%; p for heterogeneity=0.84), the risk of composite AEs (common effect model; odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the monotherapy group.

PMID:38154476 · both readings recorded this

percentage HDL-C elevation

no effect, 95% CI -0.20 to 0.17; p=0.86, p = 0.86

Likewise, the percentages HDL-C elevation (I2=0%; p for heterogeneity=0.85) were not different between the two groups (common effect model; 95% CI -0.20 to 0.17; p=0.86).

PMID:38154476 · both readings recorded this

percentage LDL-C reduction

no effect, SMD 0.08; 95% CI -0.09 to 0.26, p = 0.35

Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

PMID:38154476 · one of two readings recorded this

percentage LDL-C reduction (primary outcome)

no effect, SMD 0.08; 95% CI -0.09 to 0.26; p=0.35, p = 0.35

Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

PMID:38154476 · one of two readings recorded this

percentage reduction in LDL-C (primary outcome), plus TC, TG, HDL-C elevation, and composite adverse events, comparing 5 mg rosuvastatin/10 mg ezetimibe with 20 mg rosuvastatin monotherapy

no effect, SMD 0.08; 95% CI -0.09 to 0.26; p=0.35, p = 0.35

Not recorded as a finding: the comparison was against another active treatment

Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

PMID:38154476 · one of two readings recorded this

percentage reduction in LDL-C with rosuvastatin, compared between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin monotherapy

no effect, SMD 0.08; 95% CI -0.09 to 0.26, p = 0.35

Not recorded as a finding: the comparison was against another active treatment

Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

PMID:38154476 · one of two readings recorded this

percentage total cholesterol (TC) reduction

decreases, SMD 0.22; 95% CI 0.04 to 0.41, p = 0.02

Based on four studies (I2=47%; p for heterogeneity=0.13), the percentage TC reduction was greater in the 5 mg rosuvastatin/10 mg ezetimibe group (common effect model; SMD 0.22; 95% CI 0.04 to 0.41; p=0.02).

PMID:38154476 · both readings recorded this

percentage triglyceride (TG) reduction

no effect, SMD -0.27; 95% CI -0.84 to 0.30, p = 0.36

The percentage TG reduction of the two regimens (I2=89%; p for heterogeneity<0.01) did not differ (random effect model; SMD -0.27; 95% CI -0.84 to 0.30; p=0.36).

PMID:38154476 · both readings recorded this

LDL-C

decreases, MD -8.06, 95% CI [-9.48, -6.64] p < 0.05

Meta-analysis showed that the combination group improved LDL-C better than the monotherapy group, and the difference was statistically significant (MD -8.06, 95% CI [-9.48, -6.64] p < 0.05).

PMID:39536001 · one of two readings recorded this

LDL-C change

decreases, MD -8.06, 95% CI [-9.48, -6.64]

Meta-analysis showed that the combination group improved LDL-C better than the monotherapy group, and the difference was statistically significant (MD -8.06, 95% CI [-9.48, -6.64] p < 0.05).

PMID:39536001 · one of two readings recorded this

total cholesterol (TC)

decreases, MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05

The findings demonstrated a statistically significant difference in TC improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05].

PMID:40082758 · one of two readings recorded this

HDL-C

no effect, MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81, p = 0.81

The findings demonstrated that there was no statistically significant difference in the level of HDL-C improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81].

PMID:40082758 · one of two readings recorded this

HDL-C percentage change, CA+AA vs CC genotype

no effect, MD = -2.22, 95% CI (-19.87, 15.43), p = 0.81

The findings demonstrated that there was no statistically significant difference in the level of HDL-C improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81].

PMID:40082758 · one of two readings recorded this

total cholesterol (TC) percentage change, CA+AA vs CC genotype

decreases, MD = -7.15, 95% CI (-8.78, -5.53)

The findings demonstrated a statistically significant difference in TC improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05].

PMID:40082758 · one of two readings recorded this

triglycerides (TG)

decreases, MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05

The findings demonstrated that patients with the CA + AA genotype had a statistically significant improvement in TG compared to those with the CC genotype [MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05].

PMID:40082758 · one of two readings recorded this

triglycerides (TG) percentage change, CA+AA vs CC genotype

decreases, MD = -7.34, 95% CI (-10.88, -3.80)

The findings demonstrated that patients with the CA + AA genotype had a statistically significant improvement in TG compared to those with the CC genotype [MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05].

PMID:40082758 · one of two readings recorded this

TNF-α

decreases, n = 911

Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

PMID:40529224 · both readings recorded this

IL-6

decreases, n = 911

Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

PMID:40529224 · both readings recorded this

IL-8

decreases, n = 911

Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

PMID:40529224 · both readings recorded this

FEV1/FVC ratio

increases, n = 911

Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

PMID:40529224 · both readings recorded this

forced expiratory volume in 1 second (FEV1)

increases

Not recorded as a finding: a node exists but the paper states a different instrument or population

Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

PMID:40529224 · both readings recorded this

forced vital capacity (FVC)

increases, n = 911

Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

PMID:40529224 · both readings recorded this

galectin-3 (Gal-3)

decreases, n = 911

Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

PMID:40529224 · both readings recorded this

hs-CRP

decreases, n = 911

Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

PMID:40529224 · both readings recorded this

neutrophil elastase (NE)

decreases, n = 911

Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

PMID:40529224 · both readings recorded this

peak expiratory flow (PEF)

increases, n = 911

Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

PMID:40529224 · both readings recorded this